Takeda Pharmaceutical (TAK) Revenue Growth (3y) (2020 - 2026)
Takeda Pharmaceutical (TAK) Revenue Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 2.94% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 77.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.46% |
| Dec 31, 2025 | -2.87% |
| Sep 30, 2025 | 48.87% |
| Jun 30, 2025 | 2.63% |
| Mar 31, 2025 | -1.83% |
| Dec 31, 2024 | -4.39% |
| Sep 30, 2024 | 45.53% |
| Jun 30, 2024 | -3.65% |
| Mar 31, 2024 | 3.85% |
| Dec 31, 2023 | -3.89% |
| Sep 30, 2023 | 44.13% |
| Jun 30, 2023 | 1.19% |
| Mar 31, 2023 | 0.87% |
| Sep 30, 2022 | -1.35% |
| Jun 30, 2022 | -0.88% |
| Mar 31, 2022 | -87.30% |
| Dec 31, 2021 | 21.44% |
| Sep 30, 2021 | -87.43% |
| Jun 30, 2021 | 28.11% |
| Mar 31, 2021 | 25.30% |